Dexcom, Inc. (NASDAQ:DXCM)

DexCom, Inc., a medical device company, engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of diabetic and non-diabetic patients. Its ambulatory product line includes SEVEN PLUS and G4 PLATINUM for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments; and G4 system, a fourth generation continuous glucose monitoring system. The company’s in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. The company offers its products through direct sales organization to endocrinologists, physicians, and diabetes educators in the United States, as well as through distributors in European Union and the countries in Asia and Latin America. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.